Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
about
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in ColombiaIntrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensisClinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine AntimoniateEasy identification of leishmania species by mass spectrometrySporotrichoid leishmaniasis: a cross-sectional clinical, epidemiological and laboratory study in Rio de Janeiro State, Brazil.Leishmaniasis: a review.Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.The role of inflammatory, anti-inflammatory, and regulatory cytokines in patients infected with cutaneous leishmaniasis in Amazonas State, Brazil.Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis.Novel low-cost thermotherapy for cutaneous leishmaniasis in PeruAn update on pharmacotherapy for leishmaniasisSpecies-directed therapy for leishmaniasis in returning travellers: a comprehensive guideAmerican tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian AmazonSpecies typing in dermal leishmaniasisEfficacy and safety of a single dose pentamidine (7mg/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot studyAssociation of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern BrazilIntralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis.Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony.Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers.Evaluation of four single-locus markers for Leishmania species discrimination by sequencing.Host genetic factors in American cutaneous leishmaniasis: a critical appraisal of studies conducted in an endemic area of Brazil.Spatial distribution, Leishmania species and clinical traits of Cutaneous Leishmaniasis cases in the Colombian army.Leishmania (Viannia) naiffi: rare enough to be neglected?Identification and Biological Characterization of Leishmania (Viannia) guyanensis Isolated from a Patient with Tegumentary Leishmaniasis in Goiás, a Nonendemic Area for This Species in Brazil.New PCR assay using glucose-6-phosphate dehydrogenase for identification of Leishmania speciesProfiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study.Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles.Diagnostic Efficacy of Molecular Techniques for Detection and Identification of Leishmania Species in Human Whole Blood and Skin Samples from Ecuador.ITS1 PCR-RFLP Diagnosis and Characterization of Leishmania in Clinical Samples and Strains from Cases of Human Cutaneous Leishmaniasis in States of the Mexican Southeast.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.Early Cutaneous Leishmaniasis Patients Infected with Leishmania braziliensis Express Increased Inflammatory Responses Following Antimony Therapy.Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: An open, nonrandomized phase 2 trial.
P2860
Q28539068-07047BEE-4E65-4BFA-937E-D5F8A7BFD36BQ28543469-FE20859B-8F6C-4591-9FE4-C4006432AF7CQ28552530-76DBFA46-15A7-4359-AFFF-4908E8C73ECAQ33716734-F00D63DD-D6E4-4BB3-8AC6-5DB6EF1F1F7AQ33765054-B74A7727-7121-4A02-8798-4606FD78F4A5Q33777851-F164B18A-8700-4735-AEBA-70D8DC39FEB0Q33784151-BE9010DF-07F4-4BBD-87A9-AE498F671CC5Q34257064-62CBE017-ED80-48B0-84BD-0882D595A1EDQ34312381-29AAEF66-34CC-48D0-B1E7-3C598B3D6D7BQ34531216-808B7717-1F2C-41F3-B36B-AB2D02C563D4Q34700686-EF37342A-B5C3-420D-97A1-1F68FE9803FDQ34707782-3D97ECF6-066E-4AC1-B6D4-18F718515204Q34713385-8B2BEB21-D633-4FDF-BCB8-A6E35319BC66Q34945204-FE9EA579-44DC-4AF1-8F87-7B1F34B43081Q35160905-8565AC69-075F-474D-B983-9CE595702ECCQ35186855-6CAA80DA-BF43-43CC-B34D-5825AF08DF00Q35482538-E0867854-C1DF-4422-AA73-2C71E1A122A5Q36398273-4D55790E-B078-49C4-AA42-8A748F45EDEAQ36569120-E76B6FD1-7122-46A3-8814-88E27454EF8AQ37144991-D87C3EDD-7723-441D-B770-3FF21254A1CEQ37191345-8D7B1410-2133-4147-8E1F-6D692AB1B288Q37390612-A936518A-2E0F-46DC-B6B6-E77FAF689663Q37663500-09310E05-8C88-44BB-8550-B026F5AEDBF0Q37713425-170EC814-65B1-41BB-9088-4CDD9A51252DQ38215168-EE5EE452-FE85-4A52-8776-207F11E2AD09Q38603784-4D32853D-4522-478D-9739-C956653A1DDAQ38997665-03CD2D89-6A03-4AEB-84E1-991774A45504Q39358089-05D62312-D0C5-4E34-8D9F-7A6D31D5BCCDQ39733272-99BB2C43-DA86-474A-B22B-13BC8AE79D0BQ40078925-D8F53D3F-9632-4836-A385-DDE2EEC3551AQ41336329-A93AE5FB-B3DB-40DB-889C-61753EB94446Q41914754-6064F2FE-4CF4-4B72-9D23-D0741097DAA8Q42383560-7785925C-7564-4957-B1A6-93BC1520503EQ42742412-0E6D4283-AF1B-4829-9DAA-24329119B414Q46380663-A64A2F60-AB1B-4C4E-AF6E-173567257042Q50027467-FA8318E4-9969-4DC2-B6C3-FEFB784B0A52Q50085198-70523C03-D252-433D-B127-E003FE118CDAQ52685080-91D61C36-B354-4A76-998E-352FFBFC562A
P2860
Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Comparison of cutaneous leishm ...... onse to meglumine antimoniate.
@en
type
label
Comparison of cutaneous leishm ...... onse to meglumine antimoniate.
@en
prefLabel
Comparison of cutaneous leishm ...... onse to meglumine antimoniate.
@en
P2093
P1476
Comparison of cutaneous leishm ...... ponse to meglumine antimoniate
@en
P2093
P304
P356
10.4269/AJTMH.2001.65.456
P407
P577
2001-11-01T00:00:00Z